Different levels of treatment, including physical exercise, weight loss, and hypolipidemic agents, have the potential to modify ApoB100 metabolism in patients with metabolic syndrome, including those with ectopic skeletal muscle deposition. This evidence concerns the gene APOB and metabolic syndrome.